Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GAN Clear all
Recruiting Phase 1 Interventional

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

NCT04294043
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
Gallium nitrate
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

NCT02506647
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee insulin glargine followed by Lantus, Lantus followed by Gan & Lee insulin glargine
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 22, 2026, 5:04 AM EDT
Recruiting Phase 1 Interventional

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

NCT07543991
View directory record Official record
Conditions
Giant Axonal Neuropathy (GAN)
Interventions
scAAV9/JeT-GAN
Genetic
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jul 22, 2026, 5:04 AM EDT
Terminated No phase listed Observational

Giant Axonal Neuropathy Natural History Study

NCT01503125
View directory record Official record
Conditions
Giant Axonal Neuropathy
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Jul 22, 2026, 5:04 AM EDT
Withdrawn Phase 2 Interventional

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00836173
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
RICE, GaRD Treatment
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 2 Interventional

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00054808
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Low-Grade Lymphoma, Intermediate-Grade Lymphoma
Interventions
gallium nitrate
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Berkeley Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2006 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management

NCT00119418
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
TU 025 Keishi Bukuryo Gan
Drug
Lead sponsor
Plotnikoff, Gregory A., M.D.
Individual
Eligibility
45 Years to 58 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

NCT01093521
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
100 mg/m2 dose, 200 mg/m2 dose
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 2 Interventional

Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

NCT00002578
View directory record Official record
Conditions
Lymphoma
Interventions
cytarabine, gallium nitrate, leucovorin calcium, methotrexate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Los Angeles, California • Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Not applicable Interventional Results available

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting, Breast Cancer
Interventions
Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 5:04 AM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

NCT02362438
View directory record Official record
Conditions
Giant Axonal Neuropathy, Gene Transfer
Interventions
scAAv9/JeT-GAN
Genetic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
3 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jul 22, 2026, 5:04 AM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurodegenerative Disorders

NCT03333200
View directory record Official record
Conditions
MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
Interventions
Palliative Care, Hematopoetic Stem Cell Transplantation
Other · Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 5:04 AM EDT